Yazar "Atahan, Murat Kemal" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    An efficient biomarker panel for diagnosis of breast cancer using surface-enhanced laser desorption ionization time-of-flight mass spectrometry
    (Spandidos Publications Ltd, 2018) Yiğitbaşı, Türkan; Çalıbaşı-Kocal, Gizem; Büyükuslu, Nihal; Atahan, Murat Kemal; Küpeli, Hakan; Yiğit, Seyran; Tarcan, Ercüment; Baskın, Yasemin
    Breast cancer (BC) is the most frequently diagnosed cancer that affects women worldwide. Early detection of BC is important to improve survival rates and decrease mortality. The aim of the present study was to investigate serum biomarkers using surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) to distinguish patients with BC from the healthy population and patients with benign breast diseases (BBDs). A total of 62 patients with invasive ductal carcinoma, as confirmed by histopathology, and 47 non-cancerous individuals (NCIs) [16 healthy controls (HCs) and 31 patients with BBD] were enrolled in the present study. Serum protein profiles were determined by SELDI-TOF-MS using an immobilized metal affinity capture array. Serum from patients with BC were compared with that from the HC group using univariate and multivariate statistical analyses. A total of 118 clusters were generated from the individual serum. Univariate analysis revealed that 5 peaks were significantly downregulated (m/z 1,452, 2,670, 3,972, 5,354 and 5,523; P<0.001) and 4 were upregulated (m/z 6,850, 7,926, 8,115 and 8,143; P<0.001) in patients with BC compared with the HC group. A comparison of patients with BC and patients with BBD revealed an additional 9 protein peaks. Among these, 3 peaks (m/z 3,972, 5,336 and 11,185) were significantly downregulated and 6 peaks (m/z 4,062, 4,071, 4,609, 6,850, 8,115 and 8,133) were significantly upregulated. A total of 3 peaks [mass-to-change ratio (m/z) 3,972, 6,850 and 8,115 (BC2)] were common in both sets. The results of the present study suggest that a 4 protein peak set [m/z 3,972, 6,850 and 8,115 (BC2) and 8,949 (BC3)] could be used to distinguish patients with BC from NCI.
  • Küçük Resim Yok
    Öğe
    Seldi-tof-ms profiling of metastatic phenotype in histopathological subtypes of breast cancer
    (Bentham Science Publishers Ltd, 2018) Yiğitbaşı, Türkan; Çalıbaşı Kocal, Gizem; Büyükuslu, Nihal; Atahan, Murat Kemal; Küpeli, Hakan; Yiğit, Seyran; Tarcan, Ercüment; Baskın, Yasemin
    Background: Early detection of breast cancer is a key to the success of breast cancer management. Serum proteome analysis using Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry (SELDI-TOF-MS) generates useful information that can be utilized to describe exclusive prognostic and diagnostic biomarkers. Objective: This study aimed to use proteomics and bioinformatics to identify new biomarkers during the metastatic process of breast cancers that were classified as invasive lobular cancer or invasive ductal cancer. Method: Blood samples from 64 breast cancer patients [36 with invasive ductal cancer (14 of whom were lymph node positive); 28 with invasive lobular cancer (8 of whom were lymph node positive] were analyzed using IMAC 30 protein chips. The data acquired from the spectra were processed with univariate statistical analysis (Protein Chip Data Manager Software). Results: One-hundred-eighteen clusters were generated from the individual serum samples. Thirty-six proteins of the metastatic phenotype were found to be diagnostically accurate in cluster analysis. In the breast cancer group, a single candidate peak (m/z 1090.8) that was able to discriminate the metastatic progression was identified as a metastatic phenotype marker. Fifteen protein peaks were identified as markers to separate the histopathological subtypes as either invasive ductal cancer or invasive lobular cancer. Conclusion: In recent years, proteomic methods have rapidly become widespread in breast cancer research. This study revealed the pattern of a group of proteins that were not previously identified and are recommended as candidate markers to diagnose metastatic progression.